Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Liu, Yaxin
NCT05969184: Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC	Recruiting	2	94	RoW	CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou), Pertuzumab,Letrozole,exemestane	Peking University Cancer Hospital & Institute	Breast Neoplasm Female	12/23	12/24